On November 13, 2019 Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), reported that it has patented another TriNKET immuno-therapeutic drug for Celgene Corporation and its affiliated companies. ("Celgene") (Press release, Dragonfly Therapeutics, NOV 13, 2019, View Source;809642739.html [SID1234551223]). Today’s announcement marks Celgene’s third participation since the companies announced a malignant hematology tumor collaboration in June 2017, and follows the announcement in December 2018 by Dragonfly of the participation of Celgene to the first two immuno-therapeutic drug candidates TriNKET .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to be impressed by the quality of the candidates developed using Dragonfly’s TriNKET technology," said Rupert Vessey, FRCP DPhil, President of Research and Early Development for Celgene Corporation. "Since choosing the first two Dragonfly candidates in 2018, we have had the opportunity to further evaluate Dragonfly’s TriNKET drug candidates, and we continue to view encouraging potential therapeutic options for patients with of cancer by harnessing the power of NK cells. "

"We are pleased with the pace of our development efforts and the additional validation of our Celgene adoption adoption platform," said Bill Haney , CEO of Dragonfly. "As we move forward with our own programs, including our DF-1001 clinical stage asset, we look forward to seeing the continued progress of our partner programs. We are looking for new potential options for immuno-oncology treatment for cancer patients. "